Floatz logo

ANASTROZOLE

Hormone Receptor-Positive Breast Cancer

University of Illinois at ChicagoSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

111 Active assets in the Hormone Receptor-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB
Abemaciclib
BeOne Medicines
Phase 4BBB

View all 50 →

Same molecule, other indications

ANASTROZOLE is also rated in:

hypogonadotropic hypogonadismDormant
BBB
Indicative · Phase 4
73 / 100
View asset →
female breast carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
invasive breast carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →